The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 25, 2024
Filed:
Jul. 26, 2022
Applicant:
Beam Therapeutics Inc., Cambridge, MA (US);
Inventors:
Ian Slaymaker, Cambridge, MA (US);
Nicole Gaudelli, Cambridge, MA (US);
Yi Yu, Cambridge, MA (US);
Bernd Zetsche, Cambridge, MA (US);
David A. Born, Cambridge, MA (US);
Seung-Joo Lee, Cambridge, MA (US);
Michael Packer, Cambridge, MA (US);
Assignee:
Beam Therapeutics Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/50 (2006.01); A61K 31/7088 (2006.01); A61K 35/15 (2015.01); A61K 35/18 (2015.01); A61K 35/28 (2015.01); A61K 38/46 (2006.01); A61P 7/00 (2006.01); A61P 7/06 (2006.01); C07K 14/47 (2006.01); C12N 5/078 (2010.01); C12N 9/22 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
A61K 38/50 (2013.01); A61K 31/7088 (2013.01); A61K 35/15 (2013.01); A61K 35/18 (2013.01); A61K 35/28 (2013.01); A61K 38/465 (2013.01); A61P 7/00 (2018.01); A61P 7/06 (2018.01); C07K 14/4717 (2013.01); C12N 5/0641 (2013.01); C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12Y 305/04004 (2013.01); C07K 2319/09 (2013.01); C12N 2310/20 (2017.05); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01); C12N 2800/80 (2013.01);
Abstract
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed 'ABE8' having unprecedented levels (e.g., >60-70%) of efficiency.